328-39-2
328-39-2
Chemical Structure
(±)-Leucine
Synonym(s): DL-Leucine; (RS)-Leucine
- CAS No.: 328-39-2
- Formula:C6H13NO2
- Molecular Weight:131.17
IUPAC Name: leucine
InChIKey: ROHFNLRQFUQHCH-UHFFFAOYSA-N
SMILES: NC(CC(C)C)C(O)=O
Biological Activity: (±)-Leucine (DL-Leucine), an isomer of Leucine, chemosterilant and dietary additive. (±)-Leucine inhibits growth of Escherichia coli HfrH by 92.08%[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(±)-Leucine | 99.95% | (±)-Leucine (DL-Leucine), an isomer of Leucine, chemosterilant and dietary additive. (±)-Leucine inhibits growth of Escherichia coli HfrH by 92.08%. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-Leucine (Standard) | ≥98% | (±)-Leucine (Standard) is the analytical standard of (±)-Leucine. This product is intended for research and analytical applications. (±)-Leucine (DL-Leucine), an isomer of Leucine, chemosterilant and dietary additive. (±)-Leucine inhibits growth of Escherichia coli HfrH by 92.08%. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-Leucine-d10 | 98.0% | (±)-Leucine-d10 is the deuterium labeled (±)-Leucine. (±)-Leucine (DL-Leucine), an isomer of Leucine, chemosterilant and dietary additive. (±)-Leucine inhibits growth of Escherichia coli HfrH by 92.08%. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-Leucine-d7 | 99.89% | (±)-Leucine-d7 is the deuterium labeled (±)-Leucine. (±)-Leucine (DL-Leucine), an isomer of Leucine, chemosterilant and dietary additive. (±)-Leucine inhibits growth of Escherichia coli HfrH by 92.08%. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Alloisoleucine-d10 | L-Alloisoleucine-d10 is the deuterium labeled L-Alloisoleucine. L-Alloisoleucine is a branched chain amino acid and is a stereo-isomer of L-isoleucine. L-Alloisoleucine is a common constituent of human plasma (albeit at low levels). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Valine-d8 | 99.91% | L-Valine-d8 is a deuterated form of L-Valine (HY-N0717). L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine | 98.0% | L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-d10 | 99.0% | L-Leucine-d10 is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-13C | 99.90% | L-Leucine-13C is the 13C-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-13C6 | 99.92% | Leucine-13C6 is the 13C-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-15N | 99.84% | L-Leucine-15N is the 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-2-13C | 98% | L-Leucine-2-13C is the 13C-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-2-13C,15N | 98.0% | L-Leucine-2-13C,15N is the 13C- and 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-1-13C,15N | 99.93% | L-Leucine-1-13C,15N is the 13C- and 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-13C6,15N | 99.90% | L-Leucine-13C6,15N is the 13C- and 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Valine-d8 | 99.09% | D-Valine-d8 is the deuterium labeled D-Valine. D-Valine is the enantiomer of L-Valine (HY-N0717). L-Valine is one of 20 proteinogenic amino acids. L-Valine is an essential amino acid. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Valine-13C5,15N,d8 | L-Valine-13C5,15N,d8 ((S)-Valine-13C5,15N,d8) is the deuterium, 13C-, and 15N-labeled L-Valine (HY-N0717). L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Isoleucine-d10 | 98.6% | DL-Isoleucine-d10 is the deuterium labeled L-Isoleucine. L-isoleucine is a nonpolar hydrophobic amino acid. L-Isoleucine is an essential amino acid. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Isoleucine-d10 | 99.89% | L-Isoleucine-d10 is the deuterium labeled L-Isoleucine. L-isoleucine is a nonpolar hydrophobic amino acid. L-Isoleucine is an essential amino acid. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Isoleucine-13C6,15N,d10 | 99.9% | L-Isoleucine-13C6,15N,d10 is the deuterium, 13C-, and 15-labeled L-Isoleucine. L-isoleucine is a nonpolar hydrophobic amino acid. L-Isoleucine is an essential amino acid. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Valine-d8 | 99.96% | DL-Valine-d8 is the deuterium labeled DL-Valine. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Homoleucine | L-Homoleucine (H-HoLeu-OH) (Compound 10) is a non-proteinogenic amino acid building block. L-Homoleucinemycoplanecin is present in Mycoplanecin. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Leucine | 98.0% | D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Leucine-d10 | 99.96% | D-Leucine-d10 is the deuterium labeled D-Leucine. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
